Best Small Cell Lung Cancer Treatment Podcasts (2025)

1
WIN International Molecular Tumor Board Recommends Tailored Treatment for Advanced Colorectal Cancer 4:40

Play Pause

1d ago4:40

4:40

BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.”In this report, led by Alberto Hernando-Calvo from Vall d’Hebron U…

1
S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 26:04

2d ago26:04

26:04

Episode Description In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS Discus…

1
S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS) 24:46

3d ago24:46

24:46

Episode Description In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Discuss the mechanisms of action, eff…

1
Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer 23:31

3d ago23:31

23:31

In this podcast, Dr. Danny Nguyen from the City of Hope, Huntington Beach, CA, USA, and Dr. Edgardo S. Santos from the Oncology Institute of Hope and Innovation, Broward County, FL, USA, aim to educate on strategies to mitigate and manage dermatologic adverse events associated with amivantamab + lazertinib. This podcast is published open access in …

1
CHEK2 Identified as a Potential Target to Improve Immunotherapy in Solid Tumors 4:34

6d ago4:34

4:34

BUFFALO, NY – June 20, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.”In this paper, led by first author Helen Qian and corresponding author Crismita Dmello from Northwestern University Feinberg School of Medicine, researchers…

1
S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs 26:11

6d ago26:11

26:11

Episode Description In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they del…

1
Rare Pancreatic Cancer Patients Show Strong Response to Immunotherapy 3:53

8d ago3:53

3:53

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.”The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospital…

1
Exploring a Combined Approach: Radiation and Immunotherapy in Bladder Cancer 6:56

9d ago6:56

6:56

Bladder cancer remains a significant clinical concern, with more than 85,000 new diagnoses and nearly 19,000 deaths reported annually in the United States. While current treatments like surgery, chemotherapy, and radiation can be effective for early-stage disease, many patients with advanced or recurrent cancer face limited options.A recent review,…

1
Balancing Time, Cost, and Quality in Cardio-Oncology Care 3:21

13d ago3:21

3:21

BUFFALO, NY - June 13, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 4, 2025, titled “Applying the unattainable triangle in cardio-oncology care: Balancing cost, quality, and time.”In this review, first author John Hoverson, corresponding author Stella Pak, and colleagues from the University of Texas Health Science Center a…

1
Rare Non-Small Cell Lung Cancer with Brain Metastases Responds to Amivantamab Monotherapy 4:03

15d ago4:03

4:03

BUFFALO, NY - June 11, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.”A team led by first author Jinah Kim, from t…

1
S2 Ep31: Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies 1:04:32

15d ago1:04:32

1:04:32

Episode Description In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.…

1
Oncotarget Sponsors Open Access Team in 2025 Ride for Roswell 2:45

15d ago2:45

2:45

BUFFALO, NY — June 10, 2025 — The Ride for Roswell, one of the USA’s largest cycling events supporting cancer research, returns to Buffalo on Saturday, June 28, 2025. Hosted annually by Roswell Park Comprehensive Cancer Center, this community-wide event brings together riders, volunteers, and supporters to raise funds for cancer research, celebrate…

1
Cigarette Smoke and DNA Repair Deficiency Drive Lung Cancer Development 3:35

17d ago3:35

3:35

BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.”In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R.…

1
Experimental Triple Therapy Improves Survival in Glioblastoma Mouse Model 5:38

21d ago5:38

5:38

Researchers at Brown University have developed a combination treatment that significantly increases survival in mice with glioblastoma (GBM), a highly aggressive and treatment-resistant brain cancer. The approach uses a new class of drugs called imipridones along with radiation therapy and standard chemotherapy. This triple therapy, known as IRT, w…

1
Targeting PCNA-Androgen Receptor Interaction Suppresses Prostate Cancer Cell Growth 3:55

22d ago3:55

3:55

BUFFALO, NY - June 4, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells."In this study, authors Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated how inte…

1
Blocking PRDX1 Protein May Improve Chemotherapy Response in Ovarian Cancer 4:10

23d ago4:10

4:10

BUFFALO, NY - June 3, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling."In this study, led by first author Reem Ali and corresponding author Dindial Ramotar from Hamad Bin Khalifa University …

1
S2 Ep30: Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer 1:26:00

26d ago1:26:00

1:26:00

Episode Description This PER® Show Me Your Care Plan!™ featured podcast brings together two medical oncologists and an oncology nurse to discuss the latest advances in the management of platinum-resistant ovarian cancer (PROC). The expert panel reviews current and emerging therapies, with a special focus on the management of adverse events associat…

1
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis

27d ago

—

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According t…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

27d ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion 38:07

1M ago38:07

38:07

· In this podcast, the authors discuss the current therapeutic landscape of NSCLC with actionable alterations and provide their perspectives on treatment algorithms, and how to optimally sequence therapies for patients with tumors harboring actionable alterations, using patient cases to illustrate key principles. This podcast is published open acce…

1
Immune Side Effects of Liver Cancer Therapy Studied in Latin American Patients 4:16

1M ago4:16

4:16

BUFFALO, NY - May 23, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma."The study, led by first authors Leonardo Gomes da Fonseca from Hospital das Clí…

1
Engineered Proteins Show Promise in Stopping Glioblastoma Invasion 4:52

1M ago4:52

4:52

Scientists have engineered small, targeted proteins that can penetrate brain cancer cells and prevent them from invading healthy tissue, offering a promising new approach to treating glioblastoma multiforme (GBM), one of the deadliest forms of brain cancer. This strategy was developed by researchers at the University of Nevada, Reno, and published …

1
Combining Radiation and Immunotherapy Shows Promise for Bladder Cancer 3:45

1M ago3:45

3:45

BUFFALO, NY - May 21, 2025 – A new #review was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy."Researchers from the University of California, Irvine, led by Nazmul Hasan, reviewed recent clinical and scientific advances in combining radiation therap…

1
New Ultra-Sensitive DNA Blood Test for Detecting Residual Cancer in B-cell Lymphoma Patients 4:08

1M ago4:08

4:08

BUFFALO, NY – May 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.”In this study, a team from Foresight Diagnostics led by first author Nina Klimova and correspon…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

1M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
Blood Type A Identified as Potential Breast Cancer Risk Factor 3:19

1M ago3:19

3:19

BUFFALO, NY - May 14, 2025 – A new #review paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Relationship between ABO blood group antigens and Rh factor with breast cancer: A systematic review and meta-analysis."A comprehensive study, led by first authors Rahaf Alchazal from Yarmouk University and Khaled J. Zaitoun from Johns …

1
Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient–HCP Discussion 40:34

1M ago40:34

40:34

· In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient’s journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental impact that sarcoma had, as well as the critical role of the cancer nurse specialist within the treatment plan, alongside a pat…

1
METTL3 Drives Oral Cancer by Blocking Tumor-Suppressing Gene 3:37

2M ago3:37

3:37

BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis."In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India…

1
Panitumumab & Low-Dose Capecitabine: Promising Maintenance Therapy for Metastatic Colorectal Cancer 6:48

2M ago6:48

6:48

A recent #study from Assiut University Hospital in Egypt, published in #Oncotarget, presents a promising strategy for patients with metastatic #colorectalcancer (mCRC). The #research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patient…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

2M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Oncotarget Participation at SSP 2025 Annual Meeting 1:37

2M ago1:37

1:37

BUFFALO, NY - May 5, 2025 – Oncotarget, #published by Impact Journals, is proud to #announce its presence as an #exhibitor at the 47th Annual Meeting of the Society for Scholarly Publishing (SSP), taking place May 28–30, 2025, at the Hilton Baltimore in Maryland. Impact Journals publishes scholarly journals in the biomedical sciences, with a focus …

1
Early Immune Evasion Found in HPV-Related Pre-Cancer Lesions of the Anogenital Region 4:28

2M ago4:28

4:28

BUFFALO, NY - April 28, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on April 24, 2025, titled “PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region."Researchers Humberto Carvalho Carneiro, Rodrigo de Andrade Natal, José Vassallo and Fernando Augusto Soares from the Instituto D’…

1
Burnout Among Physicians Treating Patients with Multiple Sclerosis in the United States: A Podcast 13:52

2M ago13:52

13:52

A podcast focusing on burnout among physicians that treat patients with multiple sclerosis. This podcast is published open access in Neurology and Therapy and is fully citeable. You can access the original published podcast article through the Neurology and Therapy website and by using this link: Burnout Among Physicians Treating Patients with Mult…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

2M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
New Insights into p53: A Powerful Gene’s Role in Cancer Therapy 7:01

2M ago7:01

7:01

A new study from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, published in Oncotarget, reveals that the gene p53, long known as the “guardian of the genome,” may be even more powerful than previously thought. By studying it in non-cancerous human cells, researchers discovered how p53 stops risky cel…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

2M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Gene Variant Linked to Benign Prostate Hyperplasia Risk in Lebanese Men 4:41

2M ago4:41

4:41

BUFFALO, NY - April 15, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Association between two single nucleotide polymorphisms of the Prostaglandin-Endoperoxide Synthase 1 and 2 genes and cell proliferative prostatic diseases in Lebanon."The team of researchers led by first author Brock J. Sheehan an…

1
Protein GSK3β Offers New Angle on Overcoming Melanoma Drug Resistance 3:59

3M ago3:59

3:59

BUFFALO, NY - April 11, 2025 – A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells."In this work, first author Diana Crisan and corresponding author Abhijit Basu from the University Hospital Ulm led a team that pre…

1
Targeting SETDB1: A New Strategy for Treating Osteosarcoma 6:12

3M ago6:12

6:12

Despite decades of research, treatment for osteosarcoma has remained largely unchanged, especially for patients whose cancer spreads or returns. However, a growing body of evidence, summarized in the review “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types,” published in Oncotarget, highlights …

1
AI That Measures Its Own Uncertainty Could Improve Liver Cancer Detection 3:37

3M ago3:37

3:37

BUFFALO, NY - April 8, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques."Dr. Yashbir Singh from Mayo Clinic and his colleagues discussed how artificial intelligence (AI) can improve liver imaging b…

1
Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast 31:04

3M ago31:04

31:04

Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. Identification and management of treatment-related adverse events is key to this. In this podcast, a patient author and two healthcare professionals with real-world…

1
Triple Therapy Slows Glioblastoma Growth and Extends Survival in Preclinical Study 3:46

3M ago3:46

3:46

BUFFALO, NY - April 4, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT."Researchers from Brown University, led by first author Lanlan …

1
Single Protein Mimics Retinoic Acid Therapy to Help Leukemia Cells Mature 3:51

3M ago3:51

3:51

BUFFALO, NY - March 31, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 21, 2025, titled “FGR Src family kinase causes signaling and phenotypic shift mimicking retinoic acid-induced differentiation of leukemic cells."A research team led by first author Noor Kazim and corresponding author Andrew Yen from Cornell Univer…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

3M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
When the Cure Becomes the Cause: A Rare Case of Cancer from Donor Cells 4:57

3M ago4:57

4:57

A young woman beat leukemia; however, nine years later, she faced a different blood cancer. This rare twist, reported recently in Oncotarget, reveals an unexpected risk of bone marrow transplants and opens new questions about long-term outcomes and donor screening.Bone Marrow TransplantBone marrow transplants, also known as hematopoietic stem cell …

1
NSD2 Gene Drives Cancer Cell Identity in Multiple Myeloma 4:39

3M ago4:39

4:39

BUFFALO, NY - April 2, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma."Researchers Andrea Gunnell, Scott T. Kimber, Richard Houlston, and Martin Kaiser from The Institute of Cancer Research, London, studied how…

1
Why Some Breast Cancer Treatments Stop Working 4:11

3M ago4:11

4:11

BUFFALO, NY - March 25, 2025 – A new #review was #published in Oncotarget, Volume 16, on March 13, 2025, titled “Signaling pathway dysregulation in breast cancer."In this review article, Dinara Ryspayeva and colleagues from Brown University provide a detailed look at how breast cancer cells change the way they communicate and grow—helping tumors su…

1
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant—A Podcast 18:24

3M ago18:24

18:24

In this podcast, Dr. Marcos de Lima from the Ohio State University, Columbus, OH, USA, and Dr. David I. Marks from the University Hospitals Bristol NHS Trust, Bristol, UK, discuss real-world data obtained from the Center for International Blood and Marrow Transplant Research database to evaluate post-allogeneic hematopoietic stem cell transplantati…

1
Clear Scans Can Be Misleading: Residual Cancer Linked to Worse Outcomes 3:49

3M ago3:49

3:49

BUFFALO, NY - March 21, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on March 13, 2025, titled “No disease left behind."In this editorial, Dr. Muzamil Arshad from the University of Chicago Medical Center and colleagues highlight a growing concern in cancer care: radiotherapy may leave behind microscopic cancer even when scan ima…

1
S7 Ep1: The Importance of Spotting Endometrial Cancer 10:25

3M ago10:25

10:25

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.By CURE Talks Cancer